Tirzepatide enhances weight loss with sustained treatment but discontinuation leads to weight regain
Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain
The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year. At the same time, the study shows that remaining on the drug not only promotes additional weight loss but preserves improvements in metabolic and cardiovascular health.
The results from the SURMOUNT-4 study, which appeared Dec. ...












